Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.

Wulaningsih W, Garmo H, Ahlgren J, Holmberg L, Folkvaljon Y, Wigertz A, Van Hemelrijck M, Lambe M.

Breast Cancer Res Treat. 2018 Jul 21. doi: 10.1007/s10549-018-4890-z. [Epub ahead of print]

PMID:
30030708
2.

Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.

Moreno Berggren D, Folkvaljon Y, Engvall M, Sundberg J, Lambe M, Antunovic P, Garelius H, Lorenz F, Nilsson L, Rasmussen B, Lehmann S, Hellström-Lindberg E, Jädersten M, Ejerblad E.

Br J Haematol. 2018 Jun;181(5):614-627. doi: 10.1111/bjh.15243. Epub 2018 Apr 29.

PMID:
29707769
3.

Public online reporting from a nationwide population-based clinical prostate cancer register.

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

BJU Int. 2018 Jul;122(1):8-10. doi: 10.1111/bju.14213. Epub 2018 Apr 17. No abstract available.

4.

Temporal trends in incidence and outcome of hydatidiform mole: a retrospective cohort study.

Joneborg U, Folkvaljon Y, Papadogiannakis N, Lambe M, Marions L.

Acta Oncol. 2018 Aug;57(8):1094-1099. doi: 10.1080/0284186X.2018.1438653. Epub 2018 Feb 16.

PMID:
29451409
5.

Thyroid cancer risk in the Swedish AMORIS study: the role of inflammatory biomarkers in serum.

Ghoshal A, Garmo H, Arthur R, Carroll P, Holmberg L, Hammar N, Jungner I, Malmström H, Lambe M, Walldius G, Van Hemelrijck M.

Oncotarget. 2017 Dec 4;9(1):774-782. doi: 10.18632/oncotarget.22891. eCollection 2018 Jan 2.

6.

Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden.

Franck Lissbrant I, Ventimiglia E, Robinson D, Törnblom M, Hjälm-Eriksson M, Lambe M, Folkvaljon Y, Stattin P.

Scand J Urol. 2018 Apr;52(2):143-150. doi: 10.1080/21681805.2018.1426039. Epub 2018 Feb 1.

PMID:
29385878
7.

Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study.

Tomic K, Ventimiglia E, Robinson D, Häggström C, Lambe M, Stattin P.

Int J Cancer. 2018 Jun 15;142(12):2478-2484. doi: 10.1002/ijc.31272. Epub 2018 Feb 2.

8.

Loss in working years after a breast cancer diagnosis.

Plym A, Bower H, Fredriksson I, Holmberg L, Lambert PC, Lambe M.

Br J Cancer. 2018 Mar 6;118(5):738-743. doi: 10.1038/bjc.2017.456. Epub 2018 Jan 23.

PMID:
29360816
9.

Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study.

Arthur R, Williams R, Garmo H, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinsson D, Jungner I, Van Hemelrijck M.

Int J Cancer. 2018 Jun 1;142(11):2254-2262. doi: 10.1002/ijc.31256. Epub 2018 Jan 26.

PMID:
29322512
10.

Nordic Cancer Registries - an overview of their procedures and data comparability.

Pukkala E, Engholm G, Højsgaard Schmidt LK, Storm H, Khan S, Lambe M, Pettersson D, Ólafsdóttir E, Tryggvadóttir L, Hakanen T, Malila N, Virtanen A, Johannesen TB, Larønningen S, Ursin G.

Acta Oncol. 2018 Apr;57(4):440-455. doi: 10.1080/0284186X.2017.1407039. Epub 2017 Dec 11.

PMID:
29226751
11.

Tumor characteristics and prognosis in women with pregnancy-associated breast cancer.

Johansson ALV, Andersson TM, Hsieh CC, Jirström K, Cnattingius S, Fredriksson I, Dickman PW, Lambe M.

Int J Cancer. 2018 Apr 1;142(7):1343-1354. doi: 10.1002/ijc.31174. Epub 2017 Dec 4.

PMID:
29168177
12.

Adjusting Expected Mortality Rates Using Information From a Control Population: An Example Using Socioeconomic Status.

Bower H, Andersson TM, Crowther MJ, Dickman PW, Lambe M, Lambert PC.

Am J Epidemiol. 2018 Apr 1;187(4):828-836. doi: 10.1093/aje/kwx303.

PMID:
29020167
13.

Serum biomarkers to predict risk of testicular and penile cancer in AMORIS.

Ghoshal A, Garmo H, Arthur R, Hammar N, Jungner I, Malmström H, Lambe M, Walldius G, Hemelrijck MV.

Ecancermedicalscience. 2017 Aug 23;11:762. doi: 10.3332/ecancer.2017.762. eCollection 2017.

14.

Sex differences in cancer risk and survival: A Swedish cohort study.

Radkiewicz C, Johansson ALV, Dickman PW, Lambe M, Edgren G.

Eur J Cancer. 2017 Oct;84:130-140. doi: 10.1016/j.ejca.2017.07.013. Epub 2017 Aug 10.

PMID:
28802709
15.

The role of comorbidity in the management and prognosis in nonsmall cell lung cancer: a population-based study.

Nilsson J, Berglund A, Bergström S, Bergqvist M, Lambe M.

Acta Oncol. 2017 Jul;56(7):949-956. doi: 10.1080/0284186X.2017.1324213. Epub 2017 May 9.

PMID:
28486004
16.

No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden.

Gunnarsson N, Höglund M, Stenke L, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Wadenvik H, Richter J, Själander A.

Leukemia. 2017 Aug;31(8):1825-1827. doi: 10.1038/leu.2017.131. Epub 2017 May 2. No abstract available.

17.

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.

Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.

J Clin Oncol. 2017 May 1;35(13):1430-1436. doi: 10.1200/JCO.2016.69.5304. Epub 2017 Mar 13.

18.

Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study.

Yiu A, Van Hemelrijck M, Garmo H, Holmberg L, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Wulaningsih W.

Oncotarget. 2017 Jun 27;8(26):42332-42342. doi: 10.18632/oncotarget.16198.

19.

Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort.

Melvin JC, Garmo H, Holmberg L, Hammar N, Walldius G, Jungner I, Lambe M, Van Hemelrijck M.

BMC Cancer. 2017 Apr 4;17(1):246. doi: 10.1186/s12885-017-3232-6.

20.

Serum inflammatory markers and colorectal cancer risk and survival.

Ghuman S, Van Hemelrijck M, Garmo H, Holmberg L, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Wulaningsih W.

Br J Cancer. 2017 May 9;116(10):1358-1365. doi: 10.1038/bjc.2017.96. Epub 2017 Apr 4.

21.

Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes: findings from the Apolipoprotein Mortality Risk (AMORIS) cohort.

Shackshaft L, Van Hemelrijck M, Garmo H, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Wulaningsih W.

Breast Cancer Res. 2017 Mar 6;19(1):22. doi: 10.1186/s13058-017-0816-7.

22.

Cohort Profile: The AMORIS cohort.

Walldius G, Malmström H, Jungner I, de Faire U, Lambe M, Van Hemelrijck M, Hammar N.

Int J Epidemiol. 2017 Aug 1;46(4):1103-1103i. doi: 10.1093/ije/dyw333. No abstract available.

PMID:
28158674
23.

The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia.

Larfors G, Sandin F, Richter J, Själander A, Stenke L, Lambe M, Höglund M.

Eur J Haematol. 2017 Apr;98(4):398-406. doi: 10.1111/ejh.12845. Epub 2017 Jan 16.

PMID:
28009456
24.

Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.

Cardwell CR, Pottegård A, Vaes E, Garmo H, Murray LJ, Brown C, Vissers PA, O'Rorke M, Visvanathan K, Cronin-Fenton D, De Schutter H, Lambe M, Powe DG, van Herk-Sukel MP, Gavin A, Friis S, Sharp L, Bennett K.

Breast Cancer Res. 2016 Dec 1;18(1):119.

25.

Hypoxia-induced responses by endothelial colony-forming cells are modulated by placental growth factor.

Hookham MB, Ali IH, O'Neill CL, Hackett E, Lambe MH, Schmidt T, Medina RJ, Chamney S, Rao B, McLoone E, Sweet D, Stitt AW, Brazil DP.

Stem Cell Res Ther. 2016 Nov 29;7(1):173.

26.

Profiling cancer testis antigens in non-small-cell lung cancer.

Djureinovic D, Hallström BM, Horie M, Mattsson JS, La Fleur L, Fagerberg L, Brunnström H, Lindskog C, Madjar K, Rahnenführer J, Ekman S, Ståhle E, Koyi H, Brandén E, Edlund K, Hengstler JG, Lambe M, Saito A, Botling J, Pontén F, Uhlén M, Micke P.

JCI Insight. 2016 Jul 7;1(10):e86837.

27.

Serum Calcium and the Risk of Breast Cancer: Findings from the Swedish AMORIS Study and a Meta-Analysis of Prospective Studies.

Wulaningsih W, Sagoo HK, Hamza M, Melvin J, Holmberg L, Garmo H, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Van Hemelrijck M.

Int J Mol Sci. 2016 Sep 6;17(9). pii: E1487. doi: 10.3390/ijms17091487.

28.

A validation of DCIS registration in a population-based breast cancer quality register and a study of treatment and prognosis for DCIS during 20 years.

Wadsten C, Heyman H, Holmqvist M, Ahlgren J, Lambe M, Sund M, Wärnberg F.

Acta Oncol. 2016 Nov;55(11):1338-1343. Epub 2016 Aug 22.

PMID:
27548561
29.

Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival.

Wulaningsih W, Holmberg L, Garmo H, Karagiannis SN, Ahlstedt S, Malmstrom H, Lambe M, Hammar N, Walldius G, Jungner I, Ng T, Van Hemelrijck M.

Oncoimmunology. 2016 Mar 28;5(6):e1154250. doi: 10.1080/2162402X.2016.1154250. eCollection 2016 Jun.

30.

An investigation of routes to cancer diagnosis in 10 international jurisdictions, as part of the International Cancer Benchmarking Partnership: survey development and implementation.

Weller D, Vedsted P, Anandan C, Zalounina A, Fourkala EO, Desai R, Liston W, Jensen H, Barisic A, Gavin A, Grunfeld E, Lambe M, Law RJ, Malmberg M, Neal RD, Kalsi J, Turner D, White V, Bomb M, Menon U; ICBP Module 4 Working Group*.

BMJ Open. 2016 Jul 25;6(7):e009641. doi: 10.1136/bmjopen-2015-009641.

31.

Socioeconomic factors and penile cancer risk and mortality; a population-based study.

Torbrand C, Wigertz A, Drevin L, Folkvaljon Y, Lambe M, Håkansson U, Kirrander P.

BJU Int. 2017 Feb;119(2):254-260. doi: 10.1111/bju.13534. Epub 2016 Jul 4.

32.

Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.

Dahlén T, Edgren G, Lambe M, Höglund M, Björkholm M, Sandin F, Själander A, Richter J, Olsson-Strömberg U, Ohm L, Bäck M, Stenke L; Swedish CML Group and the Swedish CML Register Group.

Ann Intern Med. 2016 Aug 2;165(3):161-6. doi: 10.7326/M15-2306. Epub 2016 Jun 14.

PMID:
27295519
33.

Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.

Gunnarsson N, Höglund M, Stenke L, Wållberg-Jonsson S, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Wadenvik H, Richter J, Själander A.

Leukemia. 2016 Jul;30(7):1562-7. doi: 10.1038/leu.2016.59. Epub 2016 Mar 8.

PMID:
27080811
34.

Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories.

Arthur R, Møller H, Garmo H, Holmberg L, Stattin P, Malmstrom H, Lambe M, Hammar N, Walldius G, Robinson D, Jungner I, Hemelrijck MV.

Cancer Med. 2016 Jun;5(6):1307-18. doi: 10.1002/cam4.665. Epub 2016 Feb 29.

35.

Reply from Authors re: Matthew T. Gettman. Assessing Work Disability After Radical Prostatectomy. Eur Urol 2016;70:72-3: The Challenge of Assessing Work Disability.

Plym A, Voss M, Stattin P, Lambe M.

Eur Urol. 2016 Jul;70(1):73-74. doi: 10.1016/j.eururo.2016.01.040. Epub 2016 Feb 9. No abstract available.

PMID:
26873837
36.

Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.

Gunnarsson N, Sandin F, Höglund M, Stenke L, Björkholm M, Lambe M, Olsson-Strömberg U, Richter J, Själander A.

Eur J Haematol. 2016 Oct;97(4):387-92. doi: 10.1111/ejh.12743. Epub 2016 Feb 26.

PMID:
26833713
37.

Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D. F. Penson J Urol 2015;194:1710-1711.

Loeb S, Lambe M, Stattin P.

J Urol. 2016 Apr;195(4 Pt 1):1172-3. doi: 10.1016/j.juro.2015.11.040. Epub 2016 Jan 16. No abstract available.

PMID:
26783933
38.

Work Disability After Robot-assisted or Open Radical Prostatectomy: A Nationwide, Population-based Study.

Plym A, Chiesa F, Voss M, Holmberg L, Johansson E, Stattin P, Lambe M.

Eur Urol. 2016 Jul;70(1):64-71. doi: 10.1016/j.eururo.2015.12.049. Epub 2016 Jan 15.

PMID:
26782345
39.

Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study.

Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, Lambe M, Stattin P.

Int J Cancer. 2016 May 1;138(9):2154-60. doi: 10.1002/ijc.29961. Epub 2016 Jan 18.

40.

Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis.

Wulaningsih W, Vahdaninia M, Rowley M, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N, Walldius G, Jungner I, Coolen AC, Van Hemelrijck M.

BMC Cancer. 2015 Nov 17;15:913. doi: 10.1186/s12885-015-1928-z.

41.

Pregnancy history and risk of premenopausal breast cancer-a nested case-control study.

Hajiebrahimi M, Cnattingius S, Lambe M, Bahmanyar S.

Int J Epidemiol. 2016 Jun;45(3):816-24. doi: 10.1093/ije/dyv293. Epub 2015 Nov 11.

PMID:
26559546
42.

Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer.

Lu D, Sinnott JA, Valdimarsdóttir U, Fang F, Gerke T, Tyekucheva S, Fiorentino M, Lambe M, Sesso HD, Sweeney CJ, Wilson KM, Giovannucci EL, Loda M, Mucci LA, Fall K.

Clin Cancer Res. 2016 Feb 1;22(3):765-772. doi: 10.1158/1078-0432.CCR-15-0101. Epub 2015 Oct 21.

43.

Serum lactate dehydrogenase and survival following cancer diagnosis.

Wulaningsih W, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N, Walldius G, Jungner I, Ng T, Van Hemelrijck M.

Br J Cancer. 2015 Nov 3;113(9):1389-96. doi: 10.1038/bjc.2015.361. Epub 2015 Oct 15.

44.

The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml.

Stattin K, Sandin F, Bratt O, Lambe M.

J Urol. 2015 Dec;194(6):1594-600. doi: 10.1016/j.juro.2015.07.082. Epub 2015 Jul 17.

PMID:
26192253
45.

Re: Giorgio Gandaglia, Freddie Bray, Matthew R. Cooperberg, et al. Prostate Cancer Registries: Current Status and Future Directions. Eur Urol 2015;68:e110.

Stattin P, Robinson D, Lambe M.

Eur Urol. 2015 Nov;68(5):e110. doi: 10.1016/j.eururo.2015.07.002. Epub 2015 Jul 13. No abstract available.

PMID:
26184974
46.

Dashboard report on performance on select quality indicators to cancer care providers.

Stattin P, Sandin F, Sandbäck T, Damber JE, Franck Lissbrant I, Robinson D, Bratt O, Lambe M.

Scand J Urol. 2016;50(1):21-8. doi: 10.3109/21681805.2015.1063083. Epub 2015 Jul 10.

PMID:
26162012
47.

Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients.

Wulaningsih W, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N, Walldius G, Jungner I, Van Hemelrijck M.

Carcinogenesis. 2015 Oct;36(10):1121-8. doi: 10.1093/carcin/bgv096. Epub 2015 Jun 30.

PMID:
26130675
48.

Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

JAMA. 2015 Jun 23-30;313(24):2449-55. doi: 10.1001/jama.2015.6604.

PMID:
26103029
49.

[Waiting time in lung cancer care. Patient guides provided faster flow].

Holgersson G, Bergqvist M, Koyi H, Berglund A, Lambe M, Bergström S.

Lakartidningen. 2015 Jun 2;112. pii: DEYE. Swedish.

50.

The loss in expectation of life after colon cancer: a population-based study.

Andersson TM, Dickman PW, Eloranta S, Sjövall A, Lambe M, Lambert PC.

BMC Cancer. 2015 May 17;15:412. doi: 10.1186/s12885-015-1427-2.

Supplemental Content

Support Center